Pump-driven haemofiltration.

M. Storck,W. Hartl,D. Inthorn

IF: 202.731

The Lancet

Abstract:

What problem does this paper attempt to address?

Proteomic and Phosphoproteomic Maps of Lung Squamous Cell Carcinoma from Chinese Patients.

Lulu Pan,Xijun Wang,Longhai Yang,Lei Zhao,Linhui Zhai,Junyu Xu,Yikun Yang,Yousheng Mao,Shujun Cheng,Ting Xiao,Minjia Tan

DOI: https://doi.org/10.3389/fonc.2020.00963

IF: 4.7

2020-01-01

Frontiers in Oncology

Abstract:Lung squamous cell carcinoma (LUSC) is one of the leading causes of tumor-driven deaths in the world. To date, studies on the tumor heterogeneity of LUSC at genomic level have only revealed limited therapeutic benefits. Therefore, system-wide research of LUSC at proteomic level may further improve precision medicine strategies on individual demands. To this end, we performed proteomic and phosphoproteomic study for LUSC samples of 25 Chinese patients. From our results, two subgroups (Cluster I and II) based on proteomic data were identified, which were associated with distinct molecular characteristics and clinicopathologic features. Combined with phosphoproteomic data, our result showed that spliceosome pathway was enriched in Cluster I, while focal adhesion pathway, immune-related pathways and Ras signaling pathway were enriched in Cluster II. In addition, we found that lymph node metastasis (LNM) was associated with our proteomic subgroups and cell cycle pathway was enriched in patients with LNM. Further analysis showed that MCM2, a DNA replication licensing factor involved in cell cycle pathway, was highly expressed in patients with poor prognosis, which was further proved by immunohistochemistry (IHC) analysis. In summary, our study provided a resource of the proteomic and phosphoproteomic features of LUSC in Chinese patients.
LUADpp: an Effective Prediction Model on Prognosis of Lung Adenocarcinomas Based on Somatic Mutational Features

Jiaxian Yu,Yueming Hu,Yafei Xu,Jue Wang,Jiajie Kuang,Wei Zhang,Jianlin Shao,Dianjing Guo,Yejun Wang

DOI: https://doi.org/10.1186/s12885-019-5433-7

IF: 4.638

2019-01-01

BMC Cancer

Abstract:Lung adenocarcinoma is the most common type of lung cancers. Whole-genome sequencing studies disclosed the genomic landscape of lung adenocarcinomas. however, it remains unclear if the genetic alternations could guide prognosis prediction. Effective genetic markers and their based prediction models are also at a lack for prognosis evaluation. We obtained the somatic mutation data and clinical data for 371 lung adenocarcinoma cases from The Cancer Genome Atlas. The cases were classified into two prognostic groups (3-year survival), and a comparison was performed between the groups for the somatic mutation frequencies of genes, followed by development of computational models to discrete the different prognosis. Genes were found with higher mutation rates in good (≥ 3-year survival) than in poor (< 3-year survival) prognosis group of lung adenocarcinoma patients. Genes participating in cell-cell adhesion and motility were significantly enriched in the top gene list with mutation rate difference between the good and poor prognosis group. Support Vector Machine models with the gene somatic mutation features could well predict prognosis, and the performance improved as feature size increased. An 85-gene model reached an average cross-validated accuracy of 81% and an Area Under the Curve (AUC) of 0.896 for the Receiver Operating Characteristic (ROC) curves. The model also exhibited good inter-stage prognosis prediction performance, with an average AUC of 0.846 for the ROC curves. The prognosis of lung adenocarcinomas is related with somatic gene mutations. The genetic markers could be used for prognosis prediction and furthermore provide guidance for personal medicine.
Prognostic biomarker discovery based on proteome landscape of Chinese lung adenocarcinoma

Yuqi Huang,Sheng Ma,Jun-Yu Xu,Kun Qian,Yaru Wang,Yi Zhang,Minjia Tan,Ting Xiao

DOI: https://doi.org/10.1186/s12014-023-09449-2

2024-01-06

Clinical Proteomics

Abstract:Despite recent innovations in imaging and genomic screening promotes advance in diagnosis and treatment of lung adenocarcinoma (LUAD), there remains high mortality of LUAD and insufficient understanding of LUAD biology. Our previous study performed an integrative multi-omic analysis of LUAD, filling the gap between genomic alterations and their biological proteome effects. However, more detailed molecular characterization and biomarker resources at proteome level still need to be uncovered. In this study, a quantitative proteomic experiment of patient-derived benign lung disease samples was carried out. After that, we integrated the proteomic data with previous dataset of 103 paired LUAD samples. We depicted the proteomic differences between non-cancerous and tumor samples and among diverse pathological subtypes. We also found that up-regulated mitophagy was a significant characteristic of early-stage LUAD. Additionally, our integrative analysis filtered out 75 potential prognostic biomarkers and validated two of them in an independent LUAD serum cohort. This study provided insights for improved understanding proteome abnormalities of LUAD and the novel prognostic biomarker discovery offered an opportunity for LUAD precise management.

biochemical research methods
Proteomic profiling of tumor microenvironment and prognosis risk prediction in stage I lung adenocarcinoma

Yueh-Feng Lu,Ya-Hsuan Chang,Yi-Ju Chen,Min-Shu Hsieh,Mong-Wei Lin,Hsao-Hsun Hsu,Chia-Li Han,Yu-Ju Chen,Sung-Liang Yu,Jin-Shing Chen,Hsuan-Yu Chen

DOI: https://doi.org/10.1016/j.lungcan.2024.107791

IF: 6.081

Lung Cancer

Abstract:Objectives: With the increasing popularity of CT screening, more cases of early-stage lung cancer are being diagnosed. However, 24.5% of stage I non-small-cell lung cancer (NSCLC) patients still experience treatment failure post-surgery. Biomarkers to predict lung cancer patients at high risk of recurrence are needed. Materials and methods: We collected protein mass spectrometry data from the Taiwan Lung Cancer Moonshot Project and performed bioinformatics analysis on proteins with differential expressions between tumor and adjacent normal tissues in 74 stage I lung adenocarcinoma (LUAD) cases, aiming to explore the tumor microenvironment related prognostic biomarkers. Findings were further validated in 6 external cohorts. Results: The analysis of differentially expressed proteins revealed that the most enriched categories of diseases and biological functions were cellular movement, immune cell trafficking, and cancer. Utilizing proteomic profiling of the tumor microenvironment, we identified five prognostic biomarkers (ADAM10, MIF, TEK, THBS2, MAOA). We then developed a risk score model, which independently predicted recurrence-free survival and overall survival in stage I LUAD. Patients with high risk scores experienced worse recurrence-free survival (adjusted hazard ratio = 8.28, p < 0.001) and overall survival (adjusted hazard ratio = 6.88, p = 0.013). Findings had been also validated in the external cohorts. Conclusion: The risk score model derived from proteomic profiling of tumor microenvironment can be used to predict recurrence risk and prognosis of stage I LUAD.
Identification of Genes Associated with Lung Adenocarcinoma Prognosis

Zhe-Hao He,Wang Lv,Lu-Ming Wang,Yi-Qing Wang,Jian Hu

DOI: https://doi.org/10.2174/1386207322666190404152140

2019-01-01

Combinatorial Chemistry & High Throughput Screening

Abstract:Objective: Lung cancer is the most prevalent cancer in the world, and lung adenocarcinoma is the most common lung cancer subtype. Identification and determination of relevant prognostic markers are the key steps to personalized cancer management. Methods: We collected the gene expression profiles from 265 tumor tissues of stage I patients from The Cancer Genome Atlas (TCGA) databases. Using Cox regression model, we evaluated the association between gene expression and the overall survival time of patients adjusting for gender and age at initial pathologic diagnosis. Results: Age at initial pathologic diagnosis was identified to be associated with the survival, while gender was not. We identified that 15 genes were significantly associated with overall survival time of patients (FDR < 0.1). The 15-mRNA signature- based risk score was helpful to distinguish patients of high-risk group from patients of low-risk group. Conclusion: Our findings reveal novel genes associated with lung adenocarcinoma survival and extend our understanding of how gene expression contributes to lung adenocarcinoma survival. These results are helpful for the prediction of the prognosis and personalized cancer management.
Proteomic Analyses Identify Differentially Expressed Proteins and Pathways Between Low-Risk and High-Risk Subtypes of Early-Stage Lung Adenocarcinoma and Their Prognostic Impacts.

Juntuo Zhou,Bing Liu,Zhongwu Li,Yang Li,Xi Chen,Yuanyuan Ma,Shi Yan,Xin Yang,Lijun Zhong,Nan Wu

DOI: https://doi.org/10.1074/mcp.ra120.002384

IF: 7.381

2021-01-01

Molecular & Cellular Proteomics

Abstract:The histopathological subtype of lung adenocarcinoma (LUAD) is closely associated with prognosis. Micropapillary or solid predominant LUAD tends to relapse after surgery at an early stage, whereas lepidic pattern shows a favorable outcome. However, the molecular mechanism underlying this phenomenon remains unknown. Here, we recruited 31 lepidic predominant LUADs (LR: low-risk subtype group) and 28 micropapillary or solid predominant LUADs (HR: high-risk subtype group). Tissues of these cases were obtained and label-free quantitative proteomic and bioinformatic analyses were performed. Additionally, prognostic impact of targeted proteins was validated using The Cancer Genome Atlas databases (n=492) and tissue microarrays composed of early-stage LUADs (n=228). A total of 192 differentially expressed proteins were identified between tumor tissues of LR and HR and three clusters were identified via hierarchical clustering excluding eight proteins. Cluster 1 (65 proteins) showed a sequential decrease in expression from normal tissues to tumor tissues of LR and then to HR and was predominantly enriched in pathways such as tyrosine metabolism and ECM-receptor interaction, and increased matched mRNA expression of 18 proteins from this cluster predicted favorable prognosis. Cluster 2 (70 proteins) demonstrated a sequential increase in expression from normal tissues to tumor tissues of LR and then to HR and was mainly enriched in pathways such as extracellular organization, DNA replication and cell cycle, and high matched mRNA expression of 25 proteins indicated poor prognosis. Cluster 3 (49 proteins) showed high expression only in LR, with high matched mRNA expression of 20 proteins in this cluster indicating favorable prognosis. Furthermore, high expression of ERO1A and FEN1 at protein level predicted poor prognosis in early-stage LUAD, supporting the mRNA results. In conclusion, we discovered key differentially expressed proteins and pathways between low-risk and high-risk subtypes of early-stage LUAD. Some of these proteins could serve as potential biomarkers in prognostic evaluation.
Advances in the Application of Proteomics in Lung Cancer

Linquan Bai,Zhengyu Zhang,Ze Xiang,Yuepiao Cai,Xinyue Zhang,Jian Wu

DOI: https://doi.org/10.3389/fonc.2022.993781

IF: 4.7

2022-01-01

Frontiers in Oncology

Abstract:Although the incidence and mortality of lung cancer have decreased significantly in the past decade, it is still one of the leading causes of death, which greatly impairs people's life and health. Proteomics is an emerging technology that involves the application of techniques for identifying and quantifying the overall proteins in cells, tissues and organisms, and can be combined with genomics, transcriptomics to form a multi-omics research model. By comparing the content of proteins between normal and tumor tissues, proteomics can be applied to different clinical aspects like diagnosis, treatment, and prognosis, especially the exploration of disease biomarkers and therapeutic targets. The applications of proteomics have promoted the research on lung cancer. To figure out potential applications of proteomics associated with lung cancer, we summarized the role of proteomics in studies about tumorigenesis, diagnosis, prognosis, treatment and resistance of lung cancer in this review, which will provide guidance for more rational application of proteomics and potential therapeutic strategies of lung cancer.
[Use of Laser Capture Microdissection and Surface-Enhanced Laser Desorption Ionization Time-of-flight Mass Spectrometry to Screen Differential Proteins in Lung Adenocarcinoma and Lung Squamous Carcinoma].

Ying-Xuan Tian,Shuan-Ying Yang,Yan-Dong Nan,Wei Zhang,Bin Zhou,Li-Na Bu,Shu-Fen Huo,Jie-Kai Yu,Shu Zheng

DOI: https://doi.org/10.3321/j.issn:0376-2491.2008.03.001

2008-01-01

Abstract:OBJECTIVE:To screen biomarkers for classification in lung adenocarcinoma and lung squamous carcinoma by using laser capture microdissection (LCM) and surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF-MS) and support vector machine (SVM).METHODS:Six specimens of lung adenocarcinoma tissues and seven specimens of lung squamous carcinoma tissues obtained during operation were made into frozen sections and stained by improved H-E solution. About 1.2 x 10(5) of homogeneous adenocarcinoma cells and 1.4 x 10(5) of homogeneous lung squamous carcinoma cells were collected using LCM. Then SELDI profiles based on PBS II(+)SELDI-TOF-MS (IMAC protein chip) and the data were analyzed by support vector machine (SVM).RESULTS:Eighty seven differential protein peaks were found and top ten of them were identified as candidate biomarkers. The expression levels of 6 proteins among them with the molecular weights of 3333, 3592, 3848, 5036, 5191, and 5211 respectively in the lung squamous cancer tissues were weaker than those in the adenocarcinoma tissues, and the expression levels of 4 proteins with the molecular weights of 2505, 4004, 4847, and 11 412 in the lung squamous carcinoma tissues were stronger than those in the adenocarcinoma tissues. The expression of the protein with the molecular weight of 4847 in the squamous cancer was significantly stronger than that in the adenocarcinoma (p + 0.032). A discriminatory pattern consisting of 3 proteins with the molecular weights of 4847, 11 412, and 3592 was established with a sensitivity of 100% and a specificity of 100% respectively in separating adenocarcinoma from squamous carcinoma.CONCLUSION:There is a difference in protein component between adenocarcinoma and squamous carcinoma. LCM combined with SELDI-TOF-MS help screen a biomarker pattern to distinguish lung adenocarcinoma from lung squamous carcinoma with high sensitivity and specificity.
Integrative Proteomic Characterization of Human Lung Adenocarcinoma

Jun-Yu Xu,Chunchao Zhang,Xiang Wang,Linhui Zhai,Yiming Ma,Yousheng Mao,Kun Qian,Changqing Sun,Zhiwei Liu,Shangwen Jiang,Minghui Wang,Lin Feng,Lei Zhao,Ping Liu,Bo Wang,Xin Zhao,Hui Xie,Xiaoyun Yang,Liyuan Zhao,Yafei Chang,Jingya Jia,Xijun Wang,Yimin Zhang,Yaru Wang,Yikun Yang,Zhixiang Wu,Longhai Yang,Bin Liu,Teng Zhao,Shengguo Ren,Aihua Sun,Yang Zhao,Wantao Ying,Fei Wang,Guangshun Wang,Yi Zhang,Shujun Cheng,Jun Qin,Xiaohong Qian,Yi Wang,Jing Li,Fuchu He,Ting Xiao,Minjia Tan

DOI: https://doi.org/10.1016/j.cell.2020.05.043

IF: 64.5

2020-07-01

Cell

Abstract:Genomic studies of lung adenocarcinoma (LUAD) have advanced our understanding of the disease's biology and accelerated targeted therapy. However, the proteomic characteristics of LUAD remain poorly understood. We carried out a comprehensive proteomics analysis of 103 cases of LUAD in Chinese patients. Integrative analysis of proteome, phosphoproteome, transcriptome, and whole-exome sequencing data revealed cancer-associated characteristics, such as tumor-associated protein variants, distinct proteomics features, and clinical outcomes in patients at an early stage or with EGFR and TP53 mutations. Proteome-based stratification of LUAD revealed three subtypes (S-I, S-II, and S-III) related to different clinical and molecular features. Further, we nominated potential drug targets and validated the plasma protein level of HSP 90β as a potential prognostic biomarker for LUAD in an independent cohort. Our integrative proteomics analysis enables a more comprehensive understanding of the molecular landscape of LUAD and offers an opportunity for more precise diagnosis and treatment.

cell biology,biochemistry & molecular biology
A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies

Yin Li,Di Ge,Jie Gu,Fengkai Xu,Qiaoliang Zhu,Chunlai Lu

DOI: https://doi.org/10.1186/s12885-019-6101-7

IF: 4.638

2019-09-05

BMC Cancer

Abstract:<h3 class="Heading">Background</h3><p class="Para">Predicting lung adenocarcinoma (LUAD) risk is crucial in determining further treatment strategies. Molecular biomarkers may improve risk stratification for LUAD.</p><h3 class="Heading">Methods</h3><p class="Para">We analyzed the gene expression profiles of LUAD patients from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). We initially used three distinct algorithms (sigFeature, random forest, and univariate Cox regression) to evaluate each gene's prognostic relevance. Survival related genes were then fitted into the least absolute shrinkage and selection operator (LASSO) model to build a risk prediction model for LUAD. After 100,000 times of calculation and model construction, a 16-gene-based prediction model capable of classifying LUAD patients into high-risk and low-risk groups was successfully built.</p><h3 class="Heading">Results</h3><p class="Para">Using a combined strategy, we initially identified 2472 significant survival-related genes. Functional enrichment analysis demonstrated these genes' relevance to tumor initiation and progression. Using the LASSO method, we successfully built a reliable risk prediction model. The risk model was validated in two external sets and an independent set. The expression of these 16 genes was highly correlated with patients' risk. High-risk group patients witnessed poorer recurrence-free survival (RFS) and overall survival (OS) compared to low-risk group patients. Moreover, stratification analysis and decision curve analysis (DCA) confirmed the independence and potential translational value of this predictive tool. We also built a nomogram comprising risk model and stage to predict OS for LUAD patients.</p><h3 class="Heading">Conclusions</h3><p class="Para">Our risk model may serve as a practical and reliable prognosis predictive tool for LUAD and could provide novel insights into the understanding of the molecular mechanism of this disease.</p>

oncology
Comprehensive proteomic profiling of lung adenocarcinoma: development and validation of an innovative prognostic model

Xiaofei Yu,Lei Zheng,Zehai Xia,Yanling Xu,Xihui Shen,Yihui Huang,Yifan Dai

DOI: https://doi.org/10.21037/tcr-23-1940

2024-06-01

Translational Cancer Research

Abstract:Keywords: Lung adenocarcinoma (LUAD); prognostic protein model; gene set enrichment analysis (GSEA); immunotherapy sensitivity; CD38

oncology
Integrating genetic mutations and expression profiles for survival prediction of lung adenocarcinoma

Yueqiang Song,Donglai Chen,Xi Zhang,Yuping Luo,Siguang Li

DOI: https://doi.org/10.1111/1759-7714.13072

IF: 3.223

2019-04-16

Thoracic Cancer

Abstract:Lung adenocarcinoma (LUAD) is a set of heterogeneous diseases with distinct genetic and transcriptomic characteristics. Since the introduction of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society histologic classification, increasing evidence has provided insights into genomic mutations and rearrangements among individual histologic subtypes of LUAD. However, how genotypic and phenotypic features of LUAD are interconnected is not well understood.We obtained the genomic, transcriptomic, and clinical data sets of 488 LUAD patients from The Cancer Genome Atlas database. Advanced statistical models were used to disentangle the interactions between genetic mutations and expression profiles, and to assess the alterations and changes in expression of each histologic subtype. The prognostic impacts of genetic mutations, expression profiles, and clinicopathological features were integrated to predict the outcomes of LUAD patients.From our data, one or more genetic mutations correlate with expression levels of 6054/18175 (33.3%) genes and explain 8–40% of observed variability in LUAD. The genetic mutations and expression profiles varied remarkably among the histologic subtypes of LUAD, which helped to explain the different prognostic impact based on subtype classification. Genomic, transcriptomic, and clinical data were all shown to have utility for predicting overall and recurrence‐free survival, with the largest contribution from the transcriptome.Our prediction model integrating genetic mutations, expression profiles, and clinicopathological features exhibited superior accuracy over the current tumor node metastasis staging system to prognosticate outcomes of patients with LUAD (overall survival 67% vs. 55%, recurrence‐free survival 57% vs. 49%; <i>P</i>

oncology,respiratory system
Trans-omics Biomarker Model Improves Prognostic Prediction Accuracy for Early-Stage Lung Adenocarcinoma.

Xuesi Dong,Ruyang Zhang,Jieyu He,Linjing Lai,Raphael N. Alolga,Sipeng Shen,Ying Zhu,Dongfang You,Lijuan Lin,Chao Chen,Yang Zhao,Weiwei Duan,Li Su,Andrea Shafer,Moran Salama,Thomas Fleischer,Maria Moksnes Bjaanaes,Anna Karlsson,Maria Planck,Rui Wang,Johan Staaf,Aslaug Helland,Manel Esteller,Yongyue Wei,Feng Chen,David C. Christiani

DOI: https://doi.org/10.18632/aging.102189

2019-01-01

Aging

Abstract:Limited studies have focused on developing prognostic models with trans-omics biomarkers for early-stage lung adenocarcinoma (LUAD). We performed integrative analysis of clinical information, DNA methylation, and gene expression data using 825 early-stage LUAD patients from 5 cohorts. Ranger algorithm was used to screen prognosis-associated biomarkers, which were confirmed with a validation phase. Clinical and biomarker information was fused using an iCluster plus algorithm, which significantly distinguished patients into hig-hand low-mortality risk groups (P-discovery = 0.01 and P-validation = 2.71x10(-3)). Further, potential functional DNA methylation-gene expression-overall survival pathways were evaluated by causal mediation analysis. The effect of DNA methylation level on LUAD survival was significantly mediated through gene expression level. By adding DNA methylation and gene expression biomarkers to a model of only clinical data, the AUCs of the trans-omics model improved by 18.3% (to 87.2%) and 16.4% (to 85.3%) in discovery and validation phases, respectively. Further, concordance index of the nomogram was 0.81 and 0.77 in discovery and validation phases, respectively. Based on systematic review of published literatures, our model was superior to all existing models for early-stage LUAD. In summary, our trans-omics model may help physicians accurately identify patients with high mortality risk.
Proteomic analysis enables distinction of early- versus advanced-stage lung adenocarcinomas

Olga Kelemen,Indira Pla,Aniel Sanchez,Melinda Rezeli,Attila Marcell Szasz,Johan Malm,Viktoria Laszlo,Ho Jeong Kwon,Balazs Dome,Gyorgy Marko-Varga

DOI: https://doi.org/10.1002/ctm2.106

Abstract:Background: A gel-free proteomic approach was utilized to perform in-depth tissue protein profiling of lung adenocarcinoma (ADC) and normal lung tissues from early and advanced stages of the disease. The long-term goal of this study is to generate a large-scale, label-free proteomics dataset from histologically well-classified lung ADC that can be used to increase further our understanding of disease progression and aid in identifying novel biomarkers. Methods and results: Cases of early-stage (I-II) and advanced-stage (III-IV) lung ADCs were selected and paired with normal lung tissues from 22 patients. The histologically and clinically stratified human primary lung ADCs were analyzed by liquid chromatography-tandem mass spectrometry. From the analysis of ADC and normal specimens, 4863 protein groups were identified. To examine the protein expression profile of ADC, a peak area-based quantitation method was used. In early- and advanced-stage ADC, 365 and 366 proteins were differentially expressed, respectively, between normal and tumor tissues (adjusted P-value < .01, fold change ≥ 4). A total of 155 proteins were dysregulated between early- and advanced-stage ADCs and 18 were suggested as early-specific stage ADC. In silico functional analysis of the upregulated proteins in both tumor groups revealed that most of the enriched pathways are involved in mRNA metabolism. Furthermore, the most overrepresented pathways in the proteins that were unique to ADC are related to mRNA metabolic processes. Conclusions: Further analysis of these data may provide an insight into the molecular pathways involved in disease etiology and may lead to the identification of biomarker candidates and potential targets for therapy. Our study provides potential diagnostic biomarkers for lung ADC and novel stage-specific drug targets for rational intervention.
Inferior vena cava diameter and central venous pressure correlation during cardiac surgery.

S. Lorsomradee,S. Lorsomradee,S. Cromheecke,P. T. ten Broecke,S. D. De Hert

DOI: https://doi.org/10.1053/J.JVCA.2006.09.009

IF: 2.894

2007-08-01

Journal of Cardiothoracic and Vascular Anesthesia

Abstract:OBJECTIVE The purpose of this study was to determine whether a relationship exists between the inferior vena cava diameter (IVCD) or the superior vena cava diameter (SVCD) measured at the point of entry into the right atrium using transesophageal echocardiography (TEE) and the central venous pressure (CVP) under different experimental conditions. DESIGN Prospective study. SETTING University hospital, single institution. PARTICIPANTS Seventy patients undergoing elective cardiac surgery. INTERVENTIONS CVP, IVCD, and SVCD were measured in a 2-dimensional, long-axis midesophageal bicaval view at end-diastole with electrocardiographic synchronization. Data were recorded during suspended ventilation, before and after leg elevation, and at different levels of positive end-expiratory pressure (0, 5, and 10 cmH(2)O). MEASUREMENTS AND MAIN RESULTS The relationship between IVCD and CVP had 2 portions: A first (CVP <or=11 mmHg) in which the IVCD showed a strong correlation with the CVP (R = 0.801, p < 0.001; CVP = 2.009 + [0.312 * IVCD]) and a second (CVP >11 mmHg) in which the correlation was poor (R = 0.272, p = 0.065). No correlation between SVCD and CVP was observed. CONCLUSION A strong correlation between TEE-derived IVCD measured at the point of entry into the right atrium and CVP was observed in cardiac surgical patients when CVP was <or=11 mmHg.
Identification of an Immune Gene Expression Signature for Predicting Lung Squamous Cell Carcinoma Prognosis

Yubo Yan,Minghui Zhang,Shanqi Xu,Shidong Xu

DOI: https://doi.org/10.1155/2020/5024942

2020-01-01

BioMed Research International

Abstract:Growing evidence indicates that immune-related biomarkers play an important role in tumor processes. This study investigates immune-related gene expression and its prognostic value in lung squamous cell carcinoma (LUSC). A cohort of 493 samples of patients with LUSC was collected and analyzed from data generated by the TCGA Research Network and ImmPort database. The R coxph package was employed to mine significant immune-related genes using univariate analysis. Lasso and stepwise regression analyses were used to construct the LUSC prognosis prediction model, and clusterProfiler was used for gene functional annotation and enrichment analysis. The Kaplan-Meier analysis and ROC were used to evaluate the model efficiency in predicting and classifying LUSC case prognoses. We identified 14 immune-related genes to incorporate into our prognosis model. The patients were divided into two subgroups (Risk-H and Risk-L) according to their risk score values. Compared to Risk-L patients, Risk-H patients showed significantly improved overall survival (OS) in both training and testing sets. Functional annotation indicated that the 14 identified genes were mainly enriched in several immune-related pathways. Our results also revealed that a risk score value was correlated with various signaling pathways, such as the JAK-STA signaling pathway. Establishment of a nomogram for clinical application demonstrated that our immune-related model exhibited good predictive prognostic performance. Our predictive prognosis model based on immune signatures has potential clinical implications for assessing the overall survival and precise treatment for patients with LUSC.
Identification and Verification of Metabolism-related Immunotherapy Features and Prognosis in Lung Adenocarcinoma

Junfang Luo,Jinlu An,Rongyan Jia,Cong Liu,Yang Zhang

DOI: https://doi.org/10.2174/0109298673293414240314043529

IF: 4.74

2024-03-15

Current Medicinal Chemistry

Abstract:Background: Lung cancer is a frequent malignancy with a poor prognosis. Extensive metabolic alterations are involved in carcinogenesis and could, therefore, serve as a reliable prognostic phenotype. Aims: Our study aimed to develop a prognosis signature and explore the relationship between metabolic characteristic-related signature and immune infiltration in lung adenocarcinoma (LUAD) Objective: TCGA-LUAD and GSE31210 datasets were used as a training set and a validation set, respectively. Method: A total of 513 LUAD samples collected from The Cancer Genome Atlas database (TCGA-LUAD) were used as a training dataset. Molecular subtypes were classified by consensus clustering, and prognostic genes related to metabolism were analyzed based on Differentially Expressed Genes (DEGs), Protein-Protein Interaction (PPI) network, the univariate/multivariate- and Lasso- Cox regression analysis. Results: Two molecular subtypes with significant survival differences were divided by the metabolism gene sets. The DEGs between the two subtypes were identified by integrated analysis and then used to develop an 8-gene signature (TTK, TOP2A, KIF15, DLGAP5, PLK1, PTTG1, ECT2, and ANLN) for predicting LUAD prognosis. Overexpression of the 8 genes was significantly correlated with worse prognostic outcomes. RiskScore was an independent factor that could divide LUAD patients into low- and high-risk groups. Specifically, high-risk patients had poorer prognoses and higher immune escape. The Receiver Operating Characteristic (ROC) curve showed strong performance of the RiskScore model in estimating 1-, 3- and 5-year survival in both training and validation sets. Finally, an optimized nomogram model was developed and contributed the most to the prognostic prediction in LUAD. Conclusion: The current model could help effectively identify high-risk patients and suggest the most effective drug and treatment candidates for patients with LUAD.

pharmacology & pharmacy,biochemistry & molecular biology,chemistry, medicinal
The Screening of Immune-Related Biomarkers for Prognosis of Lung Adenocarcinoma

Zhonghui Liu,Dan Sun,Qing Zhu,Xinmin Liu

DOI: https://doi.org/10.1080/21655979.2021.1911211

2021-01-01

Bioengineered

Abstract:Lung adenocarcinoma (LUAD) accounts for a frequently seen non-small cell lung cancer (NSCLC) histological subtype, and it is associated with dismal prognostic outcome. However, the benefits of traditional treatment are still limited, and the efficacies of immunotherapy are quite different. Therefore, it is of great significance to identify novel immune-related therapeutic targets in lung adenocarcinoma. In this study, we identified a set of immune-related biomarkers for prognosis of lung adenocarcinoma, which could provide new ideas for immunotherapy of lung adenocarcinoma. Datasets related to LUAD were filtered from the GEO database. The appropriate packages were used to identify differentially expressed genes (DEGs) and to carry out enrichment analysis, followed by the construction of prognostic biomarkers. The Kaplan-Meier (K-M) curves were plotted to analyze patient survival based on hub genes. Associations between the expression of selected biomarkers and six types of tumor-infiltrating immune cells were evaluated based on the online tool TIMER. After analyzing five GEO datasets(GSE32867, GSE46539, GSE63459, GSE75037 and GSE116959), we discovered altogether 67 DEGs, among which, 15 showed up-regulation while 52 showed down-regulation. Enrichments of integrated DEGs were identified in the ontology categories. CAV1, CFD, FMO2 and CLEC3B were eventually selected as independent prognostic biomarkers, they were correlated with clinical outcomes of LUAD patients. Moreover, a positive correlation was observed between biomarker expression and all different types of immune infiltration, and the expression level of the four biomarkers was all positively related to macrophage.
A Prognostic Signature Model for Unveiling Tumor Progression in Lung Adenocarcinoma

Zijian Li,Tao Zeng,Chong Zhou,Yan Chen,Wu Yin

DOI: https://doi.org/10.3389/fonc.2022.1019442

IF: 4.7

2022-01-01

Frontiers in Oncology

Abstract:A more accurate prognosis is important for clinical treatment of lung adenocarcinoma. However, due to the limitation of sample and technical bias, most prognostic signatures lacked reproducibility, and few were applied to clinical practice. In addition, understanding the molecular driving mechanism is indispensable for developing more promising therapies for lung adenocarcinoma. Here, we built an unbiased prognostic significance model to perform an integrative analysis, including differentially expressed genes and clinical data with lung adenocarcinoma patients from TCGA. Multivariable Cox proportional hazards model with the Lasso penalty and 10-fold cross-validate were used to identify the best gene signature. We generated a 17-gene signature for prognostic risk prediction based on the overall survival time of lung adenocarcinoma patients. To further test the model’s predictive ability, we have applied an independent GEO database to verify the predictive ability of prognostic signature. The model can more objectively describe several biological processes related to tumors and reveal important molecular mechanisms in tumor development by GO and KEGG analysis. Furthermore, differential expression analysis by GSEA revealed that tumor microenvironments such as ER stress, exosome, and immune microenvironment were enriched. Using single-cell RNA sequence technology, we found that risk score was positively correlated with lung adenocarcinoma marker genes and copy number variation but negatively correlated with lung epithelial marker genes. High-risk cell populations with the model had stronger cancer stemness and tumor-related pathway activation. As we expected, the risk score was in accordance with the malignancy of each cluster from tumor progression. In conclusion, the risking model established in this study is more reliable than others in evaluating the prognosis of LUAD patients.
Prognostic signature based on S100 calcium-binding protein family members for lung adenocarcinoma and its clinical significance

Fengshun Zhang,Mi Zou,Chunsheng Bai,Mengjiao Zhu

DOI: https://doi.org/10.1080/10255842.2024.2376668

IF: 1.6

2024-07-18

Computer Methods in Biomechanics & Biomedical Engineering

Abstract:The S100 family proteins (S100s) participate in multiple stages of tumorigenesis and are considered to have potential value as biomarkers for detecting and predicting various cancers. But the role of S100s in lung adenocarcinoma (LUAD) prognosis is elusive. Transcriptional data of LUAD patients were retrieved from TCGA, and relevant literature was extensively reviewed to collect S100 genes. Differential gene expression analysis was performed on the LUAD data, followed by intersection analysis between the differentially expressed genes (DEGs) and S100 genes. Unsupervised consensus clustering analysis identified two clusters. Significant variations in overall survival between the two clusters were shown by Kaplan-Meier analysis. DEGs between the two clusters were analyzed using Lasso regression and univariate/multivariate Cox regression analysis, leading to construction of an 11-gene prognostic signature. The signature exhibited stable and accurate predictive capability in TCGA and GEO datasets. Subsequently, we observed distinct immune cell infiltration, immunotherapy response, and tumor mutation characteristics in high and low-risk groups. Finally, small molecular compounds targeting prognostic genes were screened using CellMiner database, and molecular docking confirmed the binding of AMG-176, Estramustine, and TAK-632 with prognostic genes. In conclusion, we generated a prognostic signature with robust and reliable predictive ability, which may provide guidance for prognosis and treatment of LUAD.

computer science, interdisciplinary applications,engineering, biomedical

Pump-driven haemofiltration.

Proteomic and Phosphoproteomic Maps of Lung Squamous Cell Carcinoma from Chinese Patients.

LUADpp: an Effective Prediction Model on Prognosis of Lung Adenocarcinomas Based on Somatic Mutational Features

Prognostic biomarker discovery based on proteome landscape of Chinese lung adenocarcinoma

Proteomic profiling of tumor microenvironment and prognosis risk prediction in stage I lung adenocarcinoma

Identification of Genes Associated with Lung Adenocarcinoma Prognosis

Proteomic Analyses Identify Differentially Expressed Proteins and Pathways Between Low-Risk and High-Risk Subtypes of Early-Stage Lung Adenocarcinoma and Their Prognostic Impacts.

Advances in the Application of Proteomics in Lung Cancer

[Use of Laser Capture Microdissection and Surface-Enhanced Laser Desorption Ionization Time-of-flight Mass Spectrometry to Screen Differential Proteins in Lung Adenocarcinoma and Lung Squamous Carcinoma].

Integrative Proteomic Characterization of Human Lung Adenocarcinoma

A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies

Comprehensive proteomic profiling of lung adenocarcinoma: development and validation of an innovative prognostic model

Integrating genetic mutations and expression profiles for survival prediction of lung adenocarcinoma

Trans-omics Biomarker Model Improves Prognostic Prediction Accuracy for Early-Stage Lung Adenocarcinoma.

Proteomic analysis enables distinction of early- versus advanced-stage lung adenocarcinomas

Inferior vena cava diameter and central venous pressure correlation during cardiac surgery.

Identification of an Immune Gene Expression Signature for Predicting Lung Squamous Cell Carcinoma Prognosis

Identification and Verification of Metabolism-related Immunotherapy Features and Prognosis in Lung Adenocarcinoma

The Screening of Immune-Related Biomarkers for Prognosis of Lung Adenocarcinoma

A Prognostic Signature Model for Unveiling Tumor Progression in Lung Adenocarcinoma

Prognostic signature based on S100 calcium-binding protein family members for lung adenocarcinoma and its clinical significance